GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclerion Therapeutics Inc (NAS:CYCN) » Definitions » Tax Rate %

Cyclerion Therapeutics (Cyclerion Therapeutics) Tax Rate % : 0.00% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Cyclerion Therapeutics Tax Rate %?

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Cyclerion Therapeutics's Tax Expense for the three months ended in Dec. 2023 was $0.00 Mil. Cyclerion Therapeutics's Pre-Tax Income for the three months ended in Dec. 2023 was $-1.69 Mil. Therefore, Cyclerion Therapeutics's Tax Rate % for the quarter that ended in Dec. 2023 was 0.00%.


Cyclerion Therapeutics Tax Rate % Historical Data

The historical data trend for Cyclerion Therapeutics's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclerion Therapeutics Tax Rate % Chart

Cyclerion Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tax Rate %
Get a 7-Day Free Trial - - - - -

Cyclerion Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Tax Rate % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Cyclerion Therapeutics Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Cyclerion Therapeutics's Tax Rate % for the fiscal year that ended in Dec. 2023 is calculated as

Tax Rate %=Tax Expense (A: Dec. 2023 )/Pre-Tax Income (A: Dec. 2023 )
=0/-12.593
=0.00 %

Cyclerion Therapeutics's Tax Rate % for the quarter that ended in Dec. 2023 is calculated as

Tax Rate %=Tax Expense (Q: Dec. 2023 )/Pre-Tax Income (Q: Dec. 2023 )
=0/-1.694
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cyclerion Therapeutics Tax Rate % Related Terms

Thank you for viewing the detailed overview of Cyclerion Therapeutics's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyclerion Therapeutics (Cyclerion Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
245 First Street, 18th Floor, Cambridge, MA, USA, 02142
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
Executives
Terrance Mcguire director C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
Steven Hyman director C/O VOYAGER THERAPEUTICS, INC., 75 SIDNEY STREET, CAMBRIDGE MA 02139
Andreas Busch officer: Chief Scientific Officer C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
George H Conrades director 500 TECHNOLOGY SQUARE, FIFTH FLOOR, CAMBRIDGE MA 02139
Stephanie Lovell director C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Ole Isacson director CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Kevin Churchwell director C/O CYCLERION THERAPEUTICS, CAMBRIDGE MA 02142
Michael Mendelsohn director C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Peter M Hecht director, officer: Chief Executive Officer C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Slate Path Capital Lp 10 percent owner 717 5TH AVENUE, 16TH FL., NEW YORK NY 10022
Errol B Desouza director 215 COLLEGE ROAD, PARAMUS NJ 07652
Anjeza Gjino officer: Chief Financial Officer C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Christopher I Wright officer: Chief Medical Officer C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Cheryl Gault officer: Chief Operating Officer CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Mark G Currie officer: President and CSO C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142

Cyclerion Therapeutics (Cyclerion Therapeutics) Headlines

From GuruFocus

Cyclerion Announces Reverse Stock Split

By sperokesalga sperokesalga 05-15-2023